ANGION
Angion Biomedica is a clinical-stage organ restoration biopharmaceutical company focused on renal disease. Its investigational drug BB3 is entering phase 3 for delayed graft function following kidney transplant and phase 2 for acute kidney injury following open-heart surgery using cardiopulmonary bypass.
ANGION
Industry:
Biopharma Biotechnology Medical
Founded:
1998-01-01
Address:
Uniondale, New York, United States
Country:
United States
Website Url:
http://www.angion.com
Total Employee:
101+
Status:
Closed
Contact:
5168691359
Email Addresses:
[email protected]
Total Funding:
84.27 M USD
Technology used in webpage:
SPF Google Maps IPv6 Microsoft Exchange Online Office 365 Mail Google Maps API Microsoft Azure DNS WooCommerce WP Engine Akamai Hosted
Similar Organizations
Adgero Biopharmaceuticals
Adgero Biopharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on building a robust pipeline
Ansun BioPharma
Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of host-directed anti-viral.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Global Blood Therapeutics
GBT is a clinical-stage biopharmaceutical company developing a therapy for sickle cell disease.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
Halo Labs
Halo Labs is a biotechnology company that specializes in analytical instrumentation and biopharma.
Peroxitech Therapeutics
Peroxitech Therapeutics operates as a biopharmaceutical company.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Employees Featured
Founder
Stock Details
Investors List
Vifor Pharma
Vifor Pharma investment in Post-IPO Equity - Angion
Formic Ventures
Formic Ventures investment in Venture Round - Angion
U.S. Department of Defense
U.S. Department of Defense investment in Grant - Angion
National Science Foundation
National Science Foundation investment in Grant - Angion
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2023-01-17 | Elicio Therapeutics | Angion investment in Debt Financing - Elicio Therapeutics | 10 M USD |
Official Site Inspections
http://www.angion.com Semrush global rank: 11.42 M Semrush visits lastest month: 162
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Angion"
Angion - Crunchbase Company Profile & Funding
Angion Biomedica is a clinical-stage organ restoration biopharmaceutical company focused on renal disease. Its investigational drug BB3 is entering phase 3 for delayed graft function following kidney transplant and phase 2 for acute …See details»
Angion's Leadership Team Team - Team members and org chart
The leadership team at Angion has a wealth of experience in the biotech industry. The CEO has led a publicly traded company and a venture capital firm, and has served on the board of …See details»
Angion Biomedica Corp.
Explore Angion Biomedica Corp. with its drug pipeline, therapeutic area, technology platform, 16 clinical trials, 103 news, and 28 literature, Disease Domain:Endocrinology and Metabolic …See details»
Angion Overview | SignalHire Company Profile
Angion is a public company that has been in the industry for 25 years. The company currently specializes in the Biotechnology, Biotechnology areas. The position of the President & CEO is …See details»
Angion Information - RocketReach
The NAICS codes for Angion are [32, 32541, 3254, 54, 541, 325]. What is the SIC code for Angion? The SIC codes for Angion are [28, 873, 283, 87]. Top Angion Employees Jay …See details»
Angion - Funding, Financials, Valuation & Investors - Crunchbase
Angion is funded by 4 investors. Vifor Pharma and Formic Ventures are the most recent investors. Angion has a post-money valuation in the range of $50M to $100M as of Jul 17, 2018, …See details»
Angion Biomedica Company Profile - Office Locations ... - Craft
Angion Biomedica has 5 employees across 2 locations, $19.74 m in total funding, and $2.3 m in annual revenue in FY 2022. See insights on Angion Biomedica including office locations, …See details»
Angion - Contacts, Employees, Board Members, Advisors
Angion Biomedica is a clinical stage organ restoration biopharmaceutical company focused on renal disease.See details»
Angion Biomedica Company Profile 2024: Valuation, Investors ...
Angion Biomedica General Information Description. Angion Biomedica Corp is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of …See details»
Angion Provides Corporate Update and Announces Participation in ...
Jan 4, 2022 Angion also expects to file an IND at the end of 2022 for a global Phase 2 trial of ANG-3070 in patients with idiopathic pulmonary fibrosis. Additional details as to patient …See details»
Angion Announces Key Addition to Management Team and …
Jun 4, 2020 Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to …See details»
Angion Announces Process to Explore Strategic Alternatives for ...
UNIONDALE, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and …See details»
ANGION BIOMEDICA CORPORATION - VentureRadar
Angion is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and …See details»
Angion hangs up 'for sale' sign, stops drug development work
Jul 26, 2022 The failures led Angion to drop the hepatocyte growth factor mimetic. In December, Angion sought to get back on track by moving the oral tyrosine kinase inhibitor ANG-3070 into …See details»
Angion Provides Corporate Update and Reports Second Quarter …
UNIONDALE, N.Y. , Aug. 15, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, …See details»
Working at Angeion Group, LLC: 19 Reviews - Indeed
Aug 14, 2024 Reviews from Angeion Group, LLC employees about Angeion Group, LLC culture, salaries, benefits, work-life balance, management, job security, and more.See details»
Renovus Capital Partners Announces Majority Investment in …
10.07.24 | News Renovus Capital Partners Announces Majority Investment in Angeion Group. Wayne, PA, October 7, 2024 – Renovus Capital Partners (“Renovus”), a private equity firm …See details»
Angeion Group is a 2024 Inc. 5000 honoree - Inc.com
Angeion Group: Internationally recognized settlement administration company leveraging world-class technology, best practices and expertise in class action and mass tort administration.See details»
Angion Provides Corporate Update and Reports First Quarter 2022 ...
May 16, 2022 -- Ended the quarter with $73M in cash and cash equivalents sufficient to fund operations well into 2023 UNIONDALE, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Angion …See details»
Angeion Group Brings Settlement Administration Into the 21st …
Jun 26, 2024 International settlement administration company Angeion is leading the shift of class member notification and settlement payment from largely paper-based to digital-based …See details»